Go to
current issue
-
Conventional chemotherapy: millions of cures, unresolved therapeutic index Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-12-16 Anthony Letai, Hugues de The
-
PDX models for functional precision oncology and discovery science Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-12-16 Zannel Blanchard, Elisabeth A. Brown, Arevik Ghazaryan, Alana L. Welm
-
Nanotubes power up T cells Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-12-03 Gabrielle Brewer
Intercellular mitochondrial transfer via tunnelling nanotubes can influence cellular bioenergetics and function in tumours. A study in Cell demonstrates how this process can increase CD8+ T cell metabolic fitness and anti-tumour function.
-
Lactate gives a sour taste Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-12-03 Daniela Senft
Wang et al. demonstrate that lactate derived from glioblastoma stem cells, microglia and macrophages drives histone lactylation, activating immunosuppressive transcriptional programs and upregulating CD47, to suppress phagocytosis.
-
Re-envisioning genetic predisposition to childhood and adolescent cancers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-12-03 Christian P. Kratz
-
Identifying memory genes in cancer drug tolerance Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-12-02 Shaon Chakrabarti
In this Journal Club, Chakrabarti discusses a method to dissect the molecular architecture of inheritable gene expression (memory) states that mark cells that transition into drug-tolerant persister cells in melanoma.
-
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-11-25 G. Paolo Dotto, An Buckinx, Berna C. Özdemir, Christian Simon
-
Chromothripsis in cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-11-15 Milena Simovic-Lorenz, Aurélie Ernst
-
Dedicated centres and multinational platforms to improve patient care and address early-onset cancers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-11-11 Irit Ben-Aharon, Elizabeth Smyth, Anna D. Wagner
The incidence of early-onset cancers has increased by approximately 80% over the past three decades. These patients have unique needs. For optimal care, designated OncoYoung programs should be created. In addition, multinational platforms with dedicated funding are necessary to investigate the aetiology of early-onset cancers and develop preventive measures. In this Comment, Ben-Aharon et al. advocate
-
Genetic and epigenetic bases of long-term adverse effects of childhood cancer therapy Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-11-07 Zhaoming Wang, Jinghui Zhang
-
Fanconi anaemia pathway induces chromosome shattering Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-11-06 Gabrielle Brewer
Engel et al. conducted a genetic screen in which they identified the Fanconi anaemia (FA) pathway as a driver of chromothripsis, complex genomic rearrangements and generation of extrachromosomal DNA.
-
Developing multiple EGFR-mutant lung cancers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-11-06 Daniela Senft
The occurrence of multiple independent tumours in patients with EGFR-mutant lung cancer was unexplained. A recent study in Nature Cancer identified distinct genetic predisposition mechanisms, including developmental mosaicism and germline EGFR variants, that contribute to the formation of multiple primary tumours.
-
Author Correction: The importance of 3D fibre architecture in cancer and implications for biomaterial model design Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-11-04 Jennifer C. Ashworth, Thomas R. Cox
Correction to: Nature Reviews Cancer https://doi.org/10.1038/s41568-024-00704-8, published online 17 June 2024.
-
Characterization of the B cell receptor repertoire in melanoma Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-11-04 Jisu Chae, Junho Chung
In this Journal Club, Chae and Chung discuss a study characterizing the differentiation and maturation of both tumour-resident and circulating B cells in patients with melanoma.
-
Midkine crisis fuels age-related tumorigenesis Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-31 Gabrielle Brewer
Ageing is a well-accepted risk factor for developing cancer. Yan et al. used a preclinical rat model to study the mechanisms facilitating the age-associated increase in breast tumorigenesis.
-
The present and future of the Cancer Dependency Map Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-28 Rand Arafeh, Tsukasa Shibue, Joshua M. Dempster, William C. Hahn, Francisca Vazquez
-
Stemness in solid malignancies: coping with immune attack Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-25 Judith Agudo, Yuxuan Miao
-
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-24 Douglas Hanahan, Olivier Michielin, Mikael J. Pittet
-
High-resolution measurement of individual telomere lengths with Telo-seq Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-22 Carly Tyer
In this Tools of the Trade article, Carly Tyer describes the development of Telo-seq, a method to enrich and sequence all telomeres within a sample, and highlights its use in distinguishing between the two telomere maintenance mechanisms used in cancer cells.
-
Emerging strategies to investigate the biology of early cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-21 Ran Zhou, Xiwen Tang, Yuan Wang
-
Epigenomic heterogeneity as a source of tumour evolution Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-16 Marthe Laisné, Mathieu Lupien, Céline Vallot
-
New horizons in our understanding of precursor multiple myeloma and early interception Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-16 David M. Cordas dos Santos, Rosa Toenges, Luca Bertamini, Jean-Baptiste Alberge, Irene M. Ghobrial
-
Immunoproteasome as a biomarker for immunotherapy Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-15 Radhakrishnan Sabarinathan
In this Journal Club, Sabarinathan discusses a study suggesting immunoproteasome expression as a potential biomarker of response to immune checkpoint inhibition in melanoma.
-
Encoding spatial tumour dynamics with Starfysh Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-11 Siyu He
In this Tools of the Trade article, Siyu He describes the development of Starfysh, a computational toolbox that integrates histology of complex tissues in spatial transcriptomic data analysis to characterize cell states.
-
Male melanoma comes of age Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-10 Daniela Senft
In a recent study published in Cell, Chhabra et al. identify age- and sex-dependent changes in skin fibroblasts that drive melanoma aggressiveness, with aged male fibroblasts promoting a slow-cycling, invasive state and resistance to targeted therapy in melanoma cells.
-
Cancer-induced systemic pre-conditioning of distant organs: building a niche for metastatic cells Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-10 Nicolas Rabas, Rute M. M. Ferreira, Stefania Di Blasio, Ilaria Malanchi
-
Compressive stresses in cancer: characterization and implications for tumour progression and treatment Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-10 Julia A. Linke, Lance L. Munn, Rakesh K. Jain
-
Steering research on mRNA splicing in cancer towards clinical translation Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-09 Olga Anczukow, Frédéric H.-T. Allain, Brittany L. Angarola, Douglas L. Black, Angela N. Brooks, Chonghui Cheng, Ana Conesa, Edie I. Crosse, Eduardo Eyras, Ernesto Guccione, Sydney X. Lu, Karla M. Neugebauer, Priyanka Sehgal, Xiao Song, Zuzana Tothova, Juan Valcárcel, Kevin M. Weeks, Gene W. Yeo, Andrei Thomas-Tikhonenko
-
Four-pronged attack on PDAC Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-08 Gabrielle Brewer
Chibaya, DeMarco et al. investigated a combinatorial approach of delivering innate immune agonists and RAS pathway-targeted therapies to remodel the tumour microenvironment and improve PDAC drug response.
-
Challenging the status quo to improve the translational potential of preclinical oncology studies Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-07 Kate Connor, Anna Golebiewska, Annette T. Byrne
The precision medicine era has precipitated inherent new challenges to the preclinical tumour biology field. Overall, continued poor clinical translatability of preclinical studies highlights the need to disrupt the status quo. Well-characterized models, ideally established in the orthotopic setting and, where feasible, treated with classical standard-of-care regimens, are mandated. In this Comment
-
Protection against tumour formation Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-04 Anna Dart
Ciwinska et al. asked whether natural tissue remodelling can drive mutant cell expansion and identified three protective mechanisms in the healthy mouse mammary gland that constrain the ability of mutant cells to transform and give rise to cancer.
-
Modelling and deciphering tumour metabolism in CRISPR screens Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-01 Johannes Zuber, Wilhelm Palm
-
Macrophages and T cells in metabolic disorder-associated cancers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-01 Daniel Taranto, Daan J. Kloosterman, Leila Akkari
-
Defining precancer: a grand challenge for the cancer community Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-10-01 Jessica Faupel-Badger, Indu Kohaar, Manisha Bahl, Andrew T. Chan, Joshua D. Campbell, Li Ding, Angelo M. De Marzo, Anirban Maitra, Daniel T. Merrick, Ernest T. Hawk, Ignacio I. Wistuba, Irene M. Ghobrial, Scott M. Lippman, Karen H. Lu, Mark Lawler, Neil E. Kay, Thea D. Tlsty, Timothy R. Rebbeck, Sudhir Srivastava
-
A standing platform for cancer drug development using ctDNA-based evidence of recurrence Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-30 Arielle J. Medford, Ariel B. Carmeli, Alexandra Ritchie, Nikhil Wagle, Levi Garraway, Eric S. Lander, Aparna Parikh
-
VIBRANT: mapping cell phenotypes using vibrational spectroscopy Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-19 Xinwen Liu
In this Tools of the Trade article, Xinwen Liu describes the development of VIBRANT, a vibrational spectroscopy method for high-content phenotypic profiling, and highlights its use to predict drug mechanisms of action or identify potential drug candidates.
-
The recruitment of metastasis-associated monocytes Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-18 Suhn Hyung Kim, Keehoon Jung
In this Journal Club, Kim and Jung discuss a study that demonstrates the role of CCL2 in recruiting monocytes to the metastasic site.
-
Managing cancer following the World Trade Center disaster Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-11 Rachel Zeig-Owens, David J. Prezant
The World Trade Center (WTC) disaster exposed individuals to carcinogens, leading to elevated cancer rates. Responders who received care through the WTC Health Program have higher survival rates. Twenty-three years post-disaster, we summarize cancer incidence and outcome studies in this population and highlight the importance of a dedicated health programme response.
-
Creating a dietary vulnerability Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-10 Daniela Senft
In a recent Nature paper, Ruggero and colleagues found that fasting and ketogenic diets induce metabolic rewiring through a translational mechanism involving MNK-mediated phosphorylation of eIF4E, which enhances ketogenesis. This process creates a metabolic vulnerability in pancreatic cancer that could be therapeutically exploited.
-
The evolutionary theory of cancer: challenges and potential solutions Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-10 Lucie Laplane, Carlo C. Maley
-
CAF-induced physical constraints controlling T cell state and localization in solid tumours Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-09 Ludovica Arpinati, Giulia Carradori, Ruth Scherz-Shouval
-
Overcoming heterogeneity with 3D whole-tumour sampling Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-06 Radhika Mathur
In this Tools of the Trade article, Radhika Mathur describes the development of a novel 3D whole-tumour sampling approach for glioblastoma, which can be used to elucidate tumour heterogeneity.
-
Intercepting gastric cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-05 Anna Dart
Pan et al. performed a large-scale, cluster-randomized controlled trial to assess whether eradicating Helicobacter pylori in asymptomatic individuals would be beneficial in preventing gastric cancer.
-
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-09-02 Mariangela Russo, Mengnuo Chen, Elisa Mariella, Haoning Peng, Sumaiyah K. Rehman, Elena Sancho, Alberto Sogari, Tzen S. Toh, Nathalie Q. Balaban, Eduard Batlle, Rene Bernards, Mathew J. Garnett, Matthew Hangauer, Eleonora Leucci, Jean-Christophe Marine, Catherine A. O’Brien, Yaara Oren, E. Elizabeth Patton, Caroline Robert, Susan M. Rosenberg, Shensi Shen, Alberto Bardelli
-
Author Correction: Integrative medicine in oncology: redefining the standard of care Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-29 Gabriel Lopez, Santhosshi Narayanan, Lorenzo Cohen
Correction to: Nature Reviews Cancer https://doi.org/10.1038/s41568-024-00735-1, published online 16 August 2024.
-
Targeting the tumour vasculature: from vessel destruction to promotion Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-29 Sophie Guelfi, Kairbaan Hodivala-Dilke, Gabriele Bergers
-
Limiting bias in AI models for improved and equitable cancer care Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-27 Marzyeh Ghassemi, Alexander Gusev
Cancer screening, diagnosis and care stand to benefit greatly from advances in artificial intelligence (AI). Researchers, developers and deployers must ensure that applications of AI avoid known racial and gender biases to advance health care for all. Cancer screening, diagnosis and care can benefit greatly from advances in artificial intelligence (AI). In this Comment, Ghassemi and Gusev discuss how
-
Thelpers? More like Ttroublemakers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-19 Gabrielle Brewer
Inflammation is well established as a risk factor for cancer development in the gut. In this study, Fesneau et al. identify a specific immune cell population, derived from T helper 17 (TH17) cells, that can initiate intestinal cancer.
-
Integrative medicine in oncology: redefining the standard of care Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-16 Gabriel Lopez, Santhosshi Narayanan, Lorenzo Cohen
Integrative medicine incorporated alongside cancer care, referred to as integrative oncology, is an evidence-informed field with established clinical guidelines. Although integrative oncology improves patient outcomes, it is inconsistently provided to patients. To align with best practices, it is necessary to increase awareness of integrative oncology, improve access to treatments, and provide consistent
-
Tracing the evolutionary history of breast cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-14 Jiwon Koh, Seock-Ah Im
In this Journal Club, Koh and Im discuss a study demonstrating the unique evolutionary trajectory of breast cancers harbouring the common driver alteration der(1;16).
-
Tertiary lymphoid structures in anticancer immunity Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-08 Jean-Luc Teillaud, Ana Houel, Marylou Panouillot, Clémence Riffard, Marie-Caroline Dieu-Nosjean
-
Publisher Correction: Structural variations in cancer and the 3D genome Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-05 Frank Dubois, Nikos Sidiropoulos, Joachim Weischenfeldt, Rameen Beroukhim
Correction to: Nature Reviews Cancer https://doi.org/10.1038/s41568-022-00488-9, published online 28 June 2022.
-
Lactate promotes DNA repair Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-05 Daniela Senft
In a recent study published in Nature, lactate has been identified as a key player in enhancing DNA repair mechanisms in gastric cancer by promoting lactylation of DNA repair proteins, leading to chemotherapy resistance.
-
Shared immunosuppressive mechanism between pregnancy and cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-08-01 Linda Gummlich
Pregnancy involves immune system suppression to protect the fetus, making it a valuable model for understanding cancer immune tolerance. Recently in Cell, Yu et al. identified B7-H4 as a common immune tolerance checkpoint in both tumours and the placenta.
-
Rational combination of cancer therapies with PD1 axis blockade Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-30
This poster explores rational combinations of immune checkpoint blockade of the PD1–PDL1 interaction with other therapies aimed at targeting effector T cells, innate immune and regulatory cells, the tumour microenvironment and cancer cells.
-
Circular RNA in cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-29 Vanessa M. Conn, Arul M. Chinnaiyan, Simon J. Conn
-
Pre-empting drug resistance Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-24 Anna Dart
Leighow et al. develop a strategy called the dual-switch selection gene drive platform, which enables the evolutionary dynamics of acquired resistance to be manipulated for therapeutic ends.
-
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-24 Nils Wellhausen, Joanne Baek, Saar I. Gill, Carl H. June
-
The impact of sex on metastasis Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-22 Yingsheng Zhang, Xue Li
-
In-depth organoid profiling of pancreatic cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-09 Ju Eun Maeng, Ja-Lok Ku
In this Journal Club, Maeng and Ku discuss a study demonstrating that profiling drug responses in patient-derived organoids can identify responders to various therapies.
更新日期：2024-11-05
Copyright © 2014-2024 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号